Recent Developments in Treating Indolent Non-Hodgkin’s Lymphoma (11/7 - NY)
November 7, 2014
The goal of this activity is to improve participants’ competence in implementing the most recent guideline changes and clinical advances in the management of patients with indolent non-Hodgkin’s lymphomas.
Target Audience
This program is intended for physicians, registered nurses, pharmacists, and other healthcare professionals who provide care for patients with indolent non-Hodgkin’s lymphomas.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Integrate evolving best practices emerging from clinical trials and guideline recommendations into the treatment of patients with indolent non-Hodgkin’s lymphomas
- Discuss with colleagues the unique mechanisms of action and biologic rationale for promising agents being developed with the potential to improve the current standard of care for patients with indolent non-Hodgkin’s lymphomas
- Evaluate ongoing clinical trials investigating novel therapies for patients with indolent non-Hodgkin’s lymphomas, suggesting clinical trial participation with appropriate patients
- Counsel patients on the known or preliminary safety profiles of approved or investigational agents and treatment strategies for indolent non-Hodgkin’s lymphomas
SUNY - Downstate
Brooklyn, NY
United States
Farrukh Awan, MD, MS
Associate Professor of Internal Medicine
Division of Hematology
The Ohio State University Comprehensive Cancer Center
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio
Available Credit
- 1.00 Participation
- 1.00 Nurse
- 1.00 Pharmacist
- 1.00 Physician
Price
Cost:
$0.00
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection
- Adobe Reader or other PDF reader software for certificate viewing/printing